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Met is one of the major contributors to the EMT-like phenotype, 
which is in turn essential for tumour invasion, metastasis and drug 
resistance. Therefore, Met signalling is a potential target to 
block tumour growth and drug resistance.  
 
Therapeutic approaches that are being currently tested: 
 
   MetMab: Anti–Met monoclonal antibody that acts as an 
antagonist of HGF. 
   Tivantinib: Met tyrosin kinase inhibitor selective for the closed 
conformation of the kinase domain.  
   Afatinib: Pan–HER inhibitor that covalently binds to the tyrosin 
kinase domain of EGFR, HER2, HER3 and HER4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Combining treatments that target several molecules, or targeting 
downstream signalling transducers, could address the common 
problem of crosstalk between signalling pathways.  
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Introduction 
Non–small cell lung cancer (NSCLC) accounts for the majority of the 
cases of lung cancer. Although being a very heterogeneous disease, 
20% of NSCLC tumours harbour activating mutations at the 
epidermal growth factor receptor (EGFR). Patients carrying such 
mutations are treated with EGFR tyrosine kinase inhibitors (TKIs), 
which have demonstrated to longer overall survival.  
 
However, patients who initially respond to EGFR TKIs will eventually 
develop drug resistance and relapse.  
 
 
 
 
 
 
 
 
 
 
 
OBJECTIVES: to characterise EMT in NSCLC and its link with 
acquired drug resistance, especially focusing on the role of Met 
signalling pathway. Also, to review some of the therapies that 
are being currently developed to tackle with NSCLC.  
 
 
EMT is characterised by: 
 
  Downregulation of E-cadherin: it is responsible for epithelial 
cell–cell adhesion and the maintenance of cytoskeleton organisation.  
  Up-regulation of mesenchymal proteins such as vimentin 
and N-cadherin.  
 
These changes enable epithelial cells to acquire a more flexible and 
migratory phenotype, described as EMT-like phenotype, which 
promotes invasion and metastasis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There are various pathways that lead to an EMT-like phenotype, 
including tyrosine kinase receptors, integrins, Wnt or TGF-β. These 
signals activate transcriptional factors  such as Snail 1, which repress 
the expression of E-cadherin and other cytokeratins  
downregulation epithelial cell–cell adhesions and loss of cell polarity. 
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Methodology 
Epithelial to mesenchymal  transition (EMT) is essential for 
acquiring drug resistance and promoting tumour metastasis in 
NSCLC, being both processes responsible for tumour progression 
and recurrence.  
Resistance to TKIs can occur through: 
 
   Primary mechanisms: K-Ras mutations present before 
treatment.  
   Secondary mechanisms shortly acquired after the initiation of 
the therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Met is a tyrosine–kinase receptor located at the surface of epithelial 
cells, which is activated by the binding of its natural ligand (HGF). In 
adult life, Met plays a role in tissue repair and organ regeneration, but 
also in human cancers – both in primary tumours and in cancer 
progression, as a secondary event that exacerbates malignant 
properties 
 
Possible  mechanisms leading to constitutive Met activation: 
 
   Transcriptional upregulation: due to hypoxic conditions, Met 
transcription is activated and causes Met protein overexpression.  
 
   HGF overexpression: HGF is a motility factor that can activate 
Met  by autocrine or paracrine signalling.  
 
 
   Crosstalk with other RTKs: in NSCLS, HER3 forms heterodimers 
with Met for the synergic activation of downstream modulators.  
 
   Met gene amplification: it is more frequently amplified in 
metastatic tumours and as a secondary event in TKIs resistant 
tumours (5 – 25% of NSCLC with acquired TKIs resistance) 
 
 
 
 
 
 
 
  
 
In NSCLC, Met constitutive activation is likely to promote the 
acquisition of an EMT-like phenotype through these intracellular 
transducers:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Met aberrant activation attenuates NSCLC addiction to EGFR signalling, 
eliminating the anti- tumour potency of EGFR TKIs. However, 
alternative mechanisms of cell survival and proliferation may appear 
after acquiring the mesenchymal phenotype (Axl, FGFR...). 
EGFR is part of the HER family of receptors, which consists of four 
members – EGFR, HER2, HER3 and HER4. Homo or 
heterodimerisation among them triggers proliferative and survival 
signals. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Adapted from: Park SM, Kim SM, Han JH. The role of epithelial-mesenchymal 
transition in gastroenterology. Korean J Gastroenterol. 2010;56(2):69-77.  
 
Activating mutations usually found on the 
tyrosine kinase domain of EGFR  
Constitutive activation and oncogene addiction 
Development of EGFR tyrosine kinase inhibitors – 
Erlotinib and Gefitinib 
(reversible competitive inhibitors of the ATP – 
binding site)  
The most promising strategy in preclinical models is the dual use 
of Met inhibitors and EGFR TKIs in tumours displaying Met gene 
amplification     
 
Although the initial phases of the studies demonstrated 
promising clinical activity, phase III results don’t show any 
benefit on the overall survival of NSCLC patients.   
 
Adapted from: Robinson KW, Sandler AB. The role of MET receptor tyrosine kinase in non-small cell 
lung cancer and clinical development of targeted anti-MET agents.Oncologist. 2013;18(2):115-122.  
 
Most data has been taken from scientific articles and reviews that are 
found in PubMed. To perform the search, some key words were used to 
select the most useful articles: epithelial–to–mesenchymal transition, 
non–small cell lung cancer, acquired drug resistance, EGFR tyrosine– 
kinase inhibitors, Met signalling, Met inhibitors. In addition, publication 
date and journal were taken into account.  
Acquired resistance 
to TKIs 
T790M: secondary point mutation in EGFR,  located in the 
ATP –binding pocket 
Kinase switch and bypass signalling mechanisms: 
compensatory activation of other tyrosine kinase receptors 
to overcome EGFR addiction 
Acquisition of EMT-like phenotype: through paracrine 
and autocrine  secretion of EMT – inducing signals 
  Cancer Stem Cells: capable of self–renewing and 
differentiation into different cellular lineages  
 
Activation of multiple signalling pathways associated to cell 
proliferation, survival, migration and invasion through various 
effectors, including mTOR, NFβ, Rac1 and MAPK 
 
Met amplification 
Crosstalk with other RTKs 
HGF overexpression 
Failure of phase III trials 
of the most promising Met 
inhibitors have put into 
doubt the potential anti –
cancer effect of this 
therapy.  
  It is essential to develop good 
biomarkers to stratify NSCLC 
patients into subgroups that 
could benefit from each 
therapy 
Anti–cancer therapies 
should focus on targeting 
cancer stem cells to 
eradicate any chance of 
relapse 
Met inhibitors would not be a 
definitive solution 
  
  Combination of EGFR tyrosine–kinase inhibitors and anti – Met 
therapies is emerging as a promising approach to improve overall 
survival of NSCLC patients  
EMT–like phenotype in NSCLC, acquired by Met aberrant 
signalling, is a determinant of marked insensitivity to EGFR TKIs. 
Targeting both Met and EGFR signalling pathways will hinder the 
early emergence of drug resistance, but they will not probably 
prevent from an eventually relapse  
